194 related articles for article (PubMed ID: 11553857)
1. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
[TBL] [Abstract][Full Text] [Related]
2. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
[TBL] [Abstract][Full Text] [Related]
3. Pyruvate kinase type tumor M2 in urological malignancies.
Hegele A; Varga Z; Kosche B; Stief T; Heidenreich A; Hofmann R
Urol Int; 2003; 70(1):55-8. PubMed ID: 12566817
[TBL] [Abstract][Full Text] [Related]
4. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
Oremek GM; Teigelkamp S; Kramer W; Eigenbrodt E; Usadel KH
Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
[TBL] [Abstract][Full Text] [Related]
5. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
6. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
Oremek GM; Sapoutzis N; Kramer W; Bickeböller R; Jonas D
Anticancer Res; 2000; 20(6D):5095-8. PubMed ID: 11326675
[TBL] [Abstract][Full Text] [Related]
7. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.
Weinberger R; Appel B; Stein A; Metz Y; Neheman A; Barak M
Eur J Cancer Care (Engl); 2007 Jul; 16(4):333-7. PubMed ID: 17587357
[TBL] [Abstract][Full Text] [Related]
8. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
[TBL] [Abstract][Full Text] [Related]
9. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma.
Roigas J; Deger S; Schroeder J; Wille A; Turk I; Brux B; Jung K; Schnorr D; Loening SA
Urol Res; 2003 Dec; 31(6):358-62. PubMed ID: 14513300
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer.
Landt S; Jeschke S; Koeninger A; Thomas A; Heusner T; Korlach S; Ulm K; Schmidt P; Blohmer JU; Lichtenegger W; Sehouli J; Kuemmel S
Anticancer Res; 2010 Feb; 30(2):375-81. PubMed ID: 20332442
[TBL] [Abstract][Full Text] [Related]
11. Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker?
Varga Z; Hegele A; Stief T; Heidenreich A; Hofmann R
Urol Res; 2002 May; 30(2):122-5. PubMed ID: 12086017
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors.
Staib P; Hoffmann M; Schinköthe T
Clin Chem Lab Med; 2006; 44(1):28-31. PubMed ID: 16375581
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
Kaura B; Bagga R; Patel FD
J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
15. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
16. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer].
Kim CW; Kim JI; Park SH; Han JY; Kim JK; Chung KW; Sun HS
Korean J Gastroenterol; 2003 Nov; 42(5):387-93. PubMed ID: 14646575
[TBL] [Abstract][Full Text] [Related]
18. Tissue specific expression and serum levels of human tissue factor in patients with urological cancer.
Förster Y; Meye A; Albrecht S; Kotzsch M; Füssel S; Wirth MP; Schwenzer B
Cancer Lett; 2003 Apr; 193(1):65-73. PubMed ID: 12691825
[TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemical demonstration of L- and M2-pyruvate kinase in primary renal cell carcinomas and their metastases].
Fischer G; Holzrichter S; Reinacher M; Heinrichs M; Dembowski J; Eigenbrodt E
Verh Dtsch Ges Pathol; 1989; 73():422-7. PubMed ID: 2482632
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
Gayed BA; Gillen J; Christie A; Peña-Llopis S; Xie XJ; Yan J; Karam JA; Raj G; Sagalowsky AI; Lotan Y; Margulis V; Brugarolas J
BMC Urol; 2015 Apr; 15():24. PubMed ID: 25885592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]